Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
66.270USD
-1.120-1.66%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
12.91BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of BridgeBio Pharma Inc is 8.42, ranking 37 out of 157 in the Pharmaceuticals industry. The average price target is 82.00, with a high of 110.00 and a low of 42.21.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
104.249
Target Price
+54.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
BridgeBio Pharma Inc
BBIO
24
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is BridgeBio Pharma Inc's expected revenue for the next quarter?
BridgeBio Pharma Inc's expected revenue is 224.74M.
What is BridgeBio Pharma Inc's price target?
Analysts forecast that BridgeBio Pharma Inc's price target is USD 82.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 42.21.
How have BridgeBio Pharma IncBBIO's recent earnings per share performed?
The market expectation was USD -0.84, while BridgeBio Pharma IncBBIO's earnings per share (EPS) for the previous quarter was USD -1.00. EPS for the next quarter is expected at USD -0.55.
What is the analyst rating for BridgeBio Pharma Inc?
Based on the ratings of BridgeBio Pharma Inc's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
